Premium
Immunophenotype of pediatric‐onset mastocytosis does not correlate with clinical course
Author(s) -
Greenberger Shoshana,
Landov Hagai,
Confino Yitzhak,
Vaknine Hananya,
Avivi Camila,
Baum Sharon,
Barzilai Aviv
Publication year - 2019
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13850
Subject(s) - cutaneous mastocytosis , medicine , immunophenotyping , mastocytoma , biopsy , pathology , systemic mastocytosis , skin biopsy , dermatology , disease , immunology , flow cytometry , cancer research , tumor cells
Background Pediatric mastocytosis differs from adult mastocytosis in its presentation and clinical course. However, the data regarding the immunophenotypic characterization of mast cells in children are limited. Our objective was to evaluate the immunophenotype of mast cells in pediatric mastocytosis and correlate it with the clinical course. Methods Biopsy specimens of children with cutaneous mastocytosis were retrieved from the institutions of pathology and were stained for CD 25, CD 2, and CD 30. The percentage of mast cells and the staining intensity were correlated with the clinical data. Results Twenty‐five biopsy specimens were included in the study. Patients’ average age was 15.4 at presentation and 37.5 months at biopsy performance. Clinical presentations included maculopapular cutaneous mastocytosis in 79% and mastocytoma in 21% of cases. CD 25, CD 2, and CD 30 were positive in 60%, 44%, and 84% of the biopsy specimens, respectively. The staining score was significantly higher for CD 30 as compared to those for CD 25 and CD 2 ( P = 0.02). No correlation was found between the immunophenotype and the clinical form or course of disease. Conclusions Our results confirm that CD 30 is a sensitive marker for pediatric‐onset mastocytosis. Nevertheless, its expression does not correlate with clinical subtype or clinical course. The sensitivity of CD 25 is higher than that of CD 2 in skin lesions.